

**Tumor Board Tuesday – Dr. Rana R. McKay, 10/11/2022:  
Biomarker Testing for Patients**

**Posttest Rationale**

**1. Which of the following HRR gene-mutations qualify for olaparib therapy?**

- a. BRCA1
- b. DSS1
- c. NBS1
- d. FANCA

**Rationale:** These HRR gene-mutations qualify for olaparib therapy per Package Insert: ATMm, BRCA1m, BRCA2m, BARD1m, BRIP1m, CDK12m, CHEK1m, CHEK2m, FANCLm, PALB2m, RAD51Bm, RAD51Cm, RAD51Dm, RAD54Lm

**Reference:** LYNPARZA<sup>®</sup> (olaparib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022.

**2. Which of the following is an FDA approved companion diagnostic for olaparib for mCRPC?**

- a. Caris Molecular Intelligence
- b. Guardant360 CDx
- c. FoundationOne Liquid CDx
- d. Myriad myChoice CDx

**Rationale:** FoundationOne Liquid CDx is the only FDA approved companion diagnostic on the multiple-choice answers that is approved for olaparib. See below for the full FDA list of cleared or approved companion diagnostic devices.

**Reference:** Center for Devices and Radiological Health. List of cleared or approved companion diagnostic devices. U.S. Food and Drug Administration. <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>. Accessed July 12, 2022.